US-based health-tech company Azra AI has launched SmartPath, an artificial intelligence (AI)-driven solution, designed to aid hospitals in managing tumour registries efficiently.

According to a press statement, recent disruptions in cancer data reporting to the NCI SEER Program have highlighted the need for such a tool.

The AI-powered tool claims to automate the process of patient data abstraction, ensuring compliance and accuracy.

Key features of the tool include automated workflows, improved efficiency, a user-friendly interface, compliance reporting, easy integration, and robust data security.

By adopting SmartPath, hospitals can enhance cancer data quality, reduce the workload on registry teams, and make data-driven decisions to improve patient care, stated Azra.

Azra AI leverages AI and machine learning to identify at-risk patients, improving healthcare outcomes and patient retention while reducing the workload on clinical staff.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This technology is currently in use at over 200 hospitals and cancer centres.

Azra AI CEO and founder Chris Cashwell said: “We understand the immense challenges hospitals face, such as staff burnout, the shortage of certified tumour registrars, and razor-thin margins.

“Given the recent, unexpected disruption in reporting to the NCI SEER Program, we recognise the urgent need for a cost-effective tumour registry alternative that can be swiftly and seamlessly implemented, ensuring continuity and compliance during these trying times.”

Cashwell added: “Many hospitals have been negatively affected, and we stand ready to collaborate with them and any hospital looking to enhance their tumour registry workflows.

“Our commitment lies in going above and beyond to ensure hospitals can continue their vital operations. Empathy and readiness define our approach, and we are here to support hospitals in every way possible.”